QuickView for DCAF1;jsessionid=F4C76F25907D3E6539736709FFBA13C5;jsessionid=71C4445269DF98EB5781D9BD69CB3BFE;jsessionid=F868F3F51D3D3F9D9ECCB4422C4CDD21;jsessionid=AFD25EC7A933D6C3DFD61F0D15B93C91;jsessionid=D90977FC693E6D84D51C4A4B99E145A3;jsessionid=4C52676849BE499043F633EB13FA50DD;jsessionid=E499AADFBA7A00DD5ECF0FF54B46B5E0;jsessionid=1BE7B111DB31BF93526F8FADD9A15ECE (gene)

1. Targeting USP2 regulation of VPRBP-mediated degradation of p53 and PD-L1 for cancer therapy.
2. The CRL4VPRBP(DCAF1) E3 ubiquitin ligase directs constitutive RAG1 degradation in a non-lymphoid cel…
3. DCAF1 regulates Treg senescence via the ROS axis during immunological aging.
4. DCAF1 controls T-cell function via p53-dependent and -independent mechanisms.
5. Isoform-specific and ubiquitination dependent recruitment of Tet1 to replicating heterochromatin mod…

There were no clinical trials for DCAF1;jsessionid=F4C76F25907D3E6539736709FFBA13C5;jsessionid=71C4445269DF98EB5781D9BD69CB3BFE;jsessionid=F868F3F51D3D3F9D9ECCB4422C4CDD21;jsessionid=AFD25EC7A933D6C3DFD61F0D15B93C91;jsessionid=D90977FC693E6D84D51C4A4B99E145A3;jsessionid=4C52676849BE499043F633EB13FA50DD;jsessionid=E499AADFBA7A00DD5ECF0FF54B46B5E0;jsessionid=1BE7B111DB31BF93526F8FADD9A15ECE